Analysis of an outbreak due to Chryseobacterium meningosepticum in a neonatal intensive care unit

New Microbiologica

Volumn 26, Issue 1, 2003, Pages 57-63

  Tekerekoglu, M S ^a   Durmaz, R ^a   Ayan, M ^a   Cizmeci, Z ^a   Akinci, A ^a  

^a INONU UNIVERSITY   (Turkey)

Author keywords

AP PCR; Chryseobacterium meningosepticum; Newborn; Outbreak; Sepsis

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; AZTREONAM; CEFOPERAZONE; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; MEROPENEM; PENICILLIN G; PIPERACILLIN; RIFAMPICIN; SULTAMICILLIN; TETRACYCLINE; TICARCILLIN; TIMENTIN; TOBRAMYCIN; VANCOMYCIN; BACTERIAL DNA;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL INFECTION; CELL CULTURE; CHRYSEOBACTERIUM MENINGOSEPTICUM; CLINICAL FEATURE; EPIDEMIC; FEMALE; HEALTH CARE PERSONNEL; HUMAN; MALE; NEWBORN; NEWBORN INTENSIVE CARE; NONHUMAN; POLYMERASE CHAIN REACTION; SEPSIS; SIDE EFFECT; TEACHING HOSPITAL; THROAT; BLOOD; CHEMISTRY; CROSS INFECTION; DISEASE TRANSMISSION; FLAVOBACTERIUM; GENETICS; GRAM NEGATIVE INFECTION; GROWTH, DEVELOPMENT AND AGING; MICROBIOLOGY; TURKEY (REPUBLIC);

BACTERIA (MICROORGANISMS); CHRYSEOBACTERIUM MENINGOSEPTICUM;

CROSS INFECTION; DISEASE OUTBREAKS; DISEASE TRANSMISSION, HORIZONTAL; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; FEMALE; FLAVOBACTERIUM; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFANT, NEWBORN; INTENSIVE CARE UNITS, NEONATAL; MALE; POLYMERASE CHAIN REACTION; SEPSIS; TURKEY;

EID: 0037271554     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. BELLAIS, S., AUBERT, D., NAAS, T., and NORDMANN, P. (2000). Molecular and biochemical heterogeneity of class B carbapenem-hydrolyzing beta-lactamases in Chryseobacterium meningosepticum. Antimicrobial Agents and Chemoterapy, 44(7), 1878-1886.
2. BLOCH, K.C., NADARAJAH, R., and JACOBS, R. (1997). Chryseobacterium meningisepticum: an emerging pathogen among immunocompromised adult. Report of 6 cases literature review. Medicine (Baltimore), 76(1), 30-41.
3. BOU, G., CERVERO, G., DOMINGUEZ, M.A., QUEREDA, C., and MARTINEZ-BELTRAN, J. (2000). PCR-based DNA fingerprinting (REP-PCR, AP-PCR) and pulsed field gel electrophoresis characterization of a nosocomial outbreak caused by imipenem- and meropenem-resistant Acinetobacter baumannii. Clinical Microbiology and Infection, 6, 635-643.
4. CHANG, J.C., HSUEH, P.R., Wu, J.J., Ho, S.W., HSIEH, W.C., and LUH, K.T. (1997). Antimicrobial susceptibility of flavobacteria as determined by agar dilution and disk diffusion methods. Antimicrobial Agents and Chemotherapy, 41 (6), 1301-1306.
5. CHIU, C.H., WADDINGDON, M., GREENBERG, D., SCHRECKENBERGER, P.C., and CARNAHAN, A.M. (2000). Atypical Chryseobacterium meningosepticum and meningitis and sepsis in newborns and the immunocompromised, Taiwan. Emerging Infectious Diseases, 6(5), 481-486.
6. DIPENTIMA, M.C., MASON, E.O., and KAPLAN, S.L. (1998). In vitro antibiotic synergy against Flavobacterium meningosepticum: implications for therapeutic options. Clinical Infectious Diseases, 26(5), 1169-1176.
7. FRASER, S.L., and JORGENSEN, J.H. (1997). Reappraisal of the antimicrobial susceptibilities of Chryseobacterium and Flavobacterium species and methods for reliable susceptibility testing. Antimicrobial Agents and Chemotherapy, 12, 2738-2741.
8. HOQUE, S.N., GRAHAM, J., KAUFMANN, M.E., and TABAQCHALI, S. (2001). Chryseobacterium (Flavobacterium) meningisepticum outbreak associated with colonization of water taps in a neonatal intensive care unit. The Journal of Hospital Infection, 47, 188-192.
9. HSUEH, P.R., TENG, L.J., YANG, P.C., HO, S.W., and LUH, K.T. (1997). Susceptibilities of Chrysebacterium indologenes and Chryseobacterium meningisepticum to cefepime and cefpirome. Journal of Clinical Microbiolgy, 35(12), 3323-3324.
10. JAMES, P.S., and CARLOS, D.R. (2000). Other Gram-negative bacilli. In: Mandell, G.L., Bennet, J.E., and Dolin, R. Eds, Principles and practice of infectious diseases. Fifth edition. Philadelphia: Churchill Livingstone. 2459-2574.
11. LIM, L.C., LOW, J.A., and CHAN, K.M. (1999). Chryseobacterium meningosepticum (Flavobacterium meningosepticum) a report of five cases in local hospital. Annals Academy Medicine Singapore, 28(6), 858-860.
12. LIU, C.E., WONG, W.W., YANG, S.P., WANG, F.D., FUNG, C.P., YOU, K.W., et al. (1999). Flavobacterium meningosepticum bacteremia: an analysis of 16 cases. Chung Hua I Hsueh Tsa Chih, 62(3), 125-132.
13. MANFREDI, R., NANETTI, A., FERRI, M., MASTROIANNI, A., CORONADO, O.V., and CHIODO, F. (1999). Flavobacterium spp. Organisms as opportunistic bacterial pathogens during advanced HIV disease. Journal of Infection, 39, 146-152.
14. NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARTS (1997). Performans Standarts for Antimicrobial Disc Susceptibility Tests, 6. edition. Approved Standart M2-A6, NCCLS, Wayne.
15. ROSSOLINI, G.M., FRANCESCHINI, N., RICCIO, M.L., MERCURI, P.S., PERILLI, M., GALLENI, M., et al. (1998). Characterization and sequence of Chryseobacterium (Flavobacterium) meningosepticum carbapenemase: a new molecular class B beta-lactamase showing a broad substrate profile. Biochemical Journal, 15, 145-152.
16. ROSSOLINI, G.M, FRANCESCHINI, N., LAURETTI, L., CARAVELLI, B., RICCIO, M.L., GALLENI, M., et al. (1999). Cloning of a Chryseobacterium (Flavobacterium) meningisepticum chromosomal gene (bIaA(CME)) encoding an extended-spectrum class A beta-lactamase related to the Bacteroides cephalosporinases and the VEB-1 and PER beta lactamases. Antimicrobial Agents and Chemotherapy, 43(9), 2193-2199.
17. SCHRECKENBERGER, P.C., and VON GRAEVENITZ, A. (1999). Acinetobacter, Achromobacter, Alcaligenes, Moraxella, Methylobacterium, and other nonfermentative gram-negative rods. In: Murray, P.R., Barron, E.J., Pfaller, M.A., Tenover, F.C., Yolken, R.H. Eds, Manual of Clinical microbiology. Seventh edition. American Society for Microbiology, Washington. D.C. (USA), 539-560.
18. YANNELLI, B., KOJ, I.G., and CUNHA, B.A. (1999). Chryseobacterium meningisepticum bacteremia secondary to central intravenous line-related infection. American Journal of Infection Control, 27, 533-535.